బ్రెస్ట్ క్యాన్సర్
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
ఎక్కడికి వెళ్లాలి
ఈ ట్రయల్ కోసం ఇండియాలోని 10 హాస్పిటల్స్ పేషెంట్లను తీసుకుంటున్నాయి.
రిజిస్ట్రీ సమ్మరీ (టెక్నికల్)
The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positive breast cancer cells have proteins on their surface called receptors that bind to hormones like estrogen and progesterone (female sex hormones). These hormones can promote the growth of cancer cells. HER2-negative describes cells that have a small amount or none of a protein called HER2 on their surface. In normal cells, HER2 helps control cell growth. Ca…
Sponsor: ఫైజర్
NCT07062965 on ClinicalTrials.gov
Last updated on the registry 19 Oct 2026 · read by us 20 Oct 2026